19 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 19 of 19 clinical reviews.
A clinical review of lemborexant (Dayvigo) and its effects on bone health and density, including orexin biology, comparative data from benzodiazepine and Z-drug studies, fall-fracture risk, and practical guidance for prescribers managing older patients with insomnia.
A physician-level review of lemborexant (Dayvigo) and cancer risk signals. Covers FDA labeling, postmarket surveillance, orexin biology, clinical trial data, and how to counsel patients asking about the Dayvigo cancer risk signal.
A clinician-level review of lemborexant (Dayvigo) cardiovascular safety data, including blood pressure, heart rate, QTc, and long-term outcomes from SUNRISE-1, SUNRISE-2, and post-market surveillance.
How lemborexant (Dayvigo) affects next-morning cognition, driving performance, and memory, based on the FDA label and the published insomnia trial literature, with notes on where independent verification of specific figures is still needed.
A physician-level comparison of compounded lemborexant vs. Branded Dayvigo covering pharmacology, clinical trial evidence, regulatory status, dosing, cost, and safety for patients and prescribers.
A GRADE-level analysis of lemborexant (Dayvigo) clinical evidence, covering SUNRISE-1, SUNRISE-2, head-to-head comparators, safety data, and what each finding means for prescribing decisions.
Does lemborexant (Dayvigo) cause hair loss or skin changes? A deep dive into the pharmacology, clinical trial data, and post-marketing reports to help you weigh the real risks.
A deep dive into how lemborexant (Dayvigo) affects liver function, hepatic metabolism, and ALT/AST levels, with primary-literature citations and dosing guidance for patients with hepatic impairment.
A clinician-level review of lemborexant (Dayvigo) and its effects on mood, anxiety, depression, and next-day cognitive function, drawing on SUNRISE-1, FDA labeling, and current sleep-psychiatry literature.
A physician-level review of lemborexant (Dayvigo) metabolism, CYP3A4 pharmacokinetics, and effects on energy expenditure, thermogenesis, and orexin-pathway physiology.
A deep dive into lemborexant (Dayvigo) microdosing protocols, covering FDA-approved dosing, the SUNRISE trial data, off-label sub-threshold use, pharmacokinetics, and what clinicians need to know before adjusting doses below 5 mg.
MD/PharmD-level guide to diagnosing and managing lemborexant (Dayvigo) plateau and non-response: dose optimization, comorbidity review, combination strategies, and when to switch agents.
A physician-level guide to the lemborexant (Dayvigo) pre-surgery hold window: pharmacokinetics, anesthesia interactions, CNS depression risk, and step-by-step perioperative management protocols.
An evidence-based guide to lemborexant (Dayvigo) rebound insomnia and discontinuation effects, covering mechanism, trial evidence, tapering strategies, and when to seek clinical support.
A deep dive into lemborexant (Dayvigo) and kidney safety. Covers pharmacokinetics, CKD dosing, clinical trial data, and practical guidance for patients with renal impairment.
Learn exactly how and when to restart lemborexant (Dayvigo) after acute illness, with dose-adjustment guidance, drug-interaction checks, and primary-literature citations prepared by the HealthRX.com Editorial Team.
A clinician-level review of lemborexant (Dayvigo) and sexual function, covering label findings, SUNRISE trial limits, orexin biology, and how to evaluate new symptoms.
A clinician-level review of how lemborexant (Dayvigo) reshapes sleep architecture, from REM and slow-wave changes to next-morning function, with primary-trial citations throughout.
Board-reviewed clinical protocols for using lemborexant (Dayvigo) during travel and timezone shifts. Covers dosing timing, jet lag physiology, SUNRISE-1 data, and next-morning alertness considerations.